Keywords
naringenin
glitsirrizin kislotasining monoammoniyli tuzi
How to Cite
Abstract
Ushbu tadqiqotda Apigenin va Naringeninning Glitsirrizin kislotasi monoammoniyli (GKMAT) va monokaliyli tuzlari (GKMKT) bilan hosil qilgan komplekslarining vazorelaksant faolligi in vitro sharoitda o‘rganildi. Tajribalar kalamush aortasining halqasimon preparatlarida izometrik qisqarish kuchini qayd etish usulida olib borildi. Qisqarish KCl (50 mM) va fenilefrin (1 µM) yordamida chaqirilib, komplekslarning ta’siri turli konsentratsiyalarda baholandi. Olingan natijalar barcha o‘rganilgan komplekslar aorta silliq mushaklarining qisqarishini konsentratsiyaga bog‘liq ravishda susaytirishini ko‘rsatdi. Ayrim komplekslarda maksimal vazorelaksant ta’siri 90% dan yuqori bo‘lib, ayniqsa GKMAT asosidagi komplekslarda yuqori faollik kuzatildi. Natijalar ushbu komplekslarning qon tomir silliq mushaklaridagi Ca2+-ga bog‘liq qisqarish mexanizmlariga ta’sir etishi mumkinligini ko‘rsatadi.References
1. Ma J., Li Y., Yang X., Liu K., Zhang X., Zuo X., Ye R., Wang Z., Shi R., Meng Q., Chen X. (2023). Signaling pathways in vascular function and hypertension: molecular mechanisms and therapeutic interventions. Signal Transduction and Targeted Therapy, 8,
168. DOI: 10.1038/s41392-023-01430-7.
2. Ghosh D., Syed A.U., Prada M.P., Nystoriak M.A., Santana L.F., Nieves-Cintrón M. (2017). Calcium channels in vascular smooth muscle. Advances in Pharmacology, 78, 49–87. DOI: 10.1016/bs.apha.2016.08.002.
3. Touyz R.M., Alves-Lopes R., Rios F.J., Camargo L.L., Anagnostopoulou A., Arner A., Montezano A.C. (2018). Vascular smooth muscle contraction in hypertension. Cardiovascular Research, 114(4), 529–539. DOI: 10.1093/cvr/cvy023.
4. Procházková D., Boušová I., Wilhelmová N. (2011). Antioxidant and prooxidant properties of flavonoids. Fitoterapia, 82(4), 513–523. DOI: 10.1016/j.fitote.2011.01.018.
5. Sánchez M., Romero M., Gómez-Guzmán M., Tamargo J., Pérez-Vizcaíno F., Duarte J. (2019). Cardiovascular effects of flavonoids. Current Medicinal Chemistry, 26(39), 6991–7034. DOI: 10.2174/0929867326666181220094721.
6. Thomas S.D., Jha N.K., Jha S.K., Sadek B., Ojha S. (2023). Pharmacological and molecular insight on the cardioprotective role of apigenin. Nutrients, 15(2),
385. DOI: 10.3390/nu15020385.
7. Zhang Y.H., Park Y.S., Kim T.J., Fang L.H., Ahn H.Y., Hong J.T., Kim Y., Lee C.K., Yun Y.P. (2000). Endothelium-dependent vasorelaxant and antiproliferative effects of apigenin. General Pharmacology, 35(6), 341–347. DOI: 10.1016/S0306-3623(02)00113-1.
8. Jing Y., Chen R., Dong M., Liu Y., Hou X., Guo P., Li W., Lv J., Zhang M. (2019). Apigenin relaxes rat intrarenal arteries, depresses Ca²⁺-activated Cl⁻ currents and augments voltage-dependent K⁺ currents of the arterial smooth muscle cells. Biomedicine & Pharmacotherapy, 115,
108926. DOI: 10.1016/j.biopha.2019.108926.
9. Gao J., Wang D., Zhang X., Yang G., Xi D., Qin X., Wang Y., Jin Y., Guo Y., Li X., Ma K. (2025). Apigenin prevents hypertensive vascular remodeling by regulating the TP53 pathway. International Immunopharmacology, 157,
114706. DOI: 10.1016/j.intimp.2025.114706.
10. Lin S.Z., Muthusamy S., Paul C.R., Saju M.K., Kuo W.W., Huang C.Y., Marthandam Asokan S. (2026). Essential pharmacokinetics and pharmacodynamics of naringenin: Underpinning the cardioprotective potential of citrus-based traditional medicine. Archiv der Pharmazie, 359(6), e70287. DOI: 10.1002/ardp.70287.
11. Orallo F., Camiña M., Alvarez E., Basaran H., Lugnier C. (2005). Implication of cyclic nucleotide phosphodiesterase inhibition in the vasorelaxant activity of the citrus-fruits flavonoid (±)-naringenin. Planta Medica, 71(2), 99–107. DOI: 10.1055/s-2005-837774.
12. Tan C.S., Tew W.Y., Jingying C., Yam M.F. (2021). Vasorelaxant effect of 5,7,4′-trihydroxyflavanone (naringenin) via endothelium dependent, potassium and calcium channels in Sprague Dawley rats: Aortic ring model. Chemico-Biological Interactions, 348,
109620. DOI: 10.1016/j.cbi.2021.109620.
13. Bakr A.F., Shao P., Farag M.A. (2022). Recent advances in glycyrrhizin metabolism, health benefits, clinical effects and drug delivery systems for efficacy improvement; a comprehensive review. Phytomedicine, 99,
153999. DOI: 10.1016/j.phymed.2022.153999.
14. Zhao Z.W., Cai M.H., Wang P., Wang D.D., Liu Y., Chen Y.Z. (2024). Application of glycyrrhizic acid and glycyrrhetinic acid in the drug delivery system. Journal of Drug Delivery Science and Technology, 97,
105754. DOI: 10.1016/j.jddst.2024.105754.
15. Feng L., Zhu M.M., Zhang M.H., Wang R.S., Tan X.B., Song J., Ding S.M., Jia X.B., Hu S.Y. (2013). Protection of glycyrrhizic acid against AGEs-induced endothelial dysfunction through inhibiting RAGE/NF-κB pathway activation in human umbilical vein endothelial cells. Journal of Ethnopharmacology, 148(1), 27–36. DOI: 10.1016/j.jep.2013.03.035.
16. Angus J.A., Wright C.E. (2000). Techniques to study the pharmacodynamics of isolated large and small blood vessels. Journal of Pharmacological and Toxicological Methods, 44(2), 395–407. DOI: 10.1016/S1056-8719(00)00121-0.